In clinical trials, to investigate the feasibility of TKI-discontinuation, half of CML patients with at least a 3 log reduction in Bcr–abl transcripts (≥0.1% International Standard) sustained a therapy free remission (TFR) [6–9]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.